研报掘金丨国盛证券：九洲药业业绩表现逐季回暖，维持买入”评级

Group 1 - The core viewpoint of the article highlights that Jiuzhou Pharmaceutical's performance is gradually improving, with the CDMO industry currently having a comparative advantage [1] - In the second quarter, the company achieved revenue of 1.381 billion yuan, representing a year-on-year increase of 7.15% [1] - The net profit attributable to the parent company for the same period was 270 million yuan [1]